Tvardi Therapeutics (LTS:0HTC) Pretax Margin %: % (As of Mar. 2026)


What is Tvardi Therapeutics Pretax Margin %?

Tvardi Therapeutics LTS:0HTC 12 Pretax Margin % is % as of Mar. 2026. GuruFocus rates LTS:0HTC with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 943 Biotechnology companies, Tvardi Therapeutics ranks worse than 106044.43% on this metric.

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Tvardi Therapeutics's Pre-Tax Income for the three months ended in Mar. 2026 was £-5.10 Mil. Tvardi Therapeutics's Revenue for the three months ended in Mar. 2026 was £0.00 Mil. Therefore, Tvardi Therapeutics's pretax margin for the quarter that ended in Mar. 2026 was %.

The historical rank and industry rank for Tvardi Therapeutics's Pretax Margin % or its related term are showing as below:


LTS:0HTC's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -90.63
* Ranked among companies with meaningful Pretax Margin % only.

Tvardi Therapeutics  (LTS:0HTC) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.

Tvardi Therapeutics Pretax Margin % Related Terms

Tvardi Therapeutics Pretax Margin % Historical Data

* Premium members only.

The historical data trend for Tvardi Therapeutics's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tvardi Therapeutics Pretax Margin % Chart

Tvardi Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Pretax Margin %
0.00 0.00 0.00 0.00

Tvardi Therapeutics Quarterly Data
Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

LTS:0HTC vs HOWL, TPST, XCUR: Pretax Margin % Comparison

For the Biotechnology subindustry, Tvardi Therapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tvardi Therapeutics Pretax Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tvardi Therapeutics's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Tvardi Therapeutics's Pretax Margin % falls into.


Tvardi Therapeutics Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Tvardi Therapeutics's Pretax Margin for the fiscal year that ended in Dec. 2025 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-13.606/0
= %

Tvardi Therapeutics's Pretax Margin for the quarter that ended in Mar. 2026 is calculated as

Pretax Margin=Pre-Tax Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-5.103/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Pretax Margin % →
What does a Pretax Margin % of % mean?
Tvardi Therapeutics (LTS:0HTC) has a Pretax Margin % of % as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Tvardi Therapeutics and its competitors. According to the industry distribution chart, Tvardi Therapeutics ranks #999999 out of 943 companies in the Biotechnology industry.
Is Tvardi Therapeutics' Pretax Margin % too high?
Tvardi Therapeutics' current Pretax Margin % is %. Based on the distribution chart, Tvardi Therapeutics ranks #999999 out of 943 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Tvardi Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Tvardi Therapeutics' Pretax Margin % compare to HOWL and TPST?
According to the Biotechnology industry distribution chart, Tvardi Therapeutics ranks #999999 out of 943 companies for Pretax Margin %. This places Tvardi Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Tvardi Therapeutics and its competitors. Tvardi Therapeutics's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tvardi Therapeutics stock overvalued right now?
Tvardi Therapeutics (LTS:0HTC) has a current Pretax Margin % of %. The current Pretax Margin % is %. Tvardi Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Tvardi Therapeutics (LTS:0HTC), the current Pretax Margin % is % as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tvardi Therapeutics Business Description

Other Exchanges TVRD:USA69C:Germany
Address 3 Sugar Creek Center boulevard, Suite 525, Sugar Land, TX, USA, 77478
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.